Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Pediatrics Regulation

EU Pilots New 'Stepwise' Approach To Pediatric Investigation Plans

  • News

Executive Summary

New EU guidance has been published to help the European Medicines Agency and drug developers agree on the conduct of pediatric investigation plans (PIPs) when crucial information is not yet available. 

You may also be interested in...



Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion

Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.

UK ABPI Suspends Novo Nordisk Over Code Breach

Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.

BMS Decides Against Opdualag Launch In Germany

BMS says that recent reforms to the benefit assessment system have led to the “deterioration” of the German market. 

Table

View full table

Topics

Tags:
Europe Pediatrics Regulation
Latest Headlines

Pink Sheet Podcast: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS

Moderna And The All-American Drug Pricing Hearing

US FDA Formalizes ‘One-Trial’ Approach For Oncology Accelerated Approval

EMA Report Highlights Parallel Regulatory/HTA Consultations Among Achievements

See All
UsernamePublicRestriction

Register

PS147697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By